RAC
RACE ONCOLOGY LTD
$1.93
▼ -5.85%
Market cap
$378M
Turnover
$162,552
Last price
$1.93
Day change
-5.85%
Announcements
14
Range, past year
Open 3.030 · Low 1.040 · Now 1.930 · High 4.900
Open RAC in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
RAC momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-09-28.
Momentum quality
33/100
Wyckoff phase
Downtrend14d
Trend stage
Breakdown
1 Day
-5.9%
1 Week
-7.7%
1 Month
-10.2%
1 Year
-38.3%
RSI
38
Avg daily range
4.8%
RACE ONCOLOGY LTD scores 33 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Breakdown.
On the Wyckoff cycle it sits in Downtrend, where it has been for 14 trading days. The weekly timeframe reads Downtrend, which agrees with the daily view.
Against the wider market it is currently underperforming and the institutional accumulation signal reads low.
Points to watch
- Risk rating: High
- Composite downside risk elevated
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highsRAC announcements
Recent price-sensitive releases.
- 2026-09-01 CPACS Trial Opens for RC220 Patient Enrolment in Korea Progress Report
- 2026-08-25 Appendix 4E & Annual Report Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-07-29 First HARNESS-1 Patient Safely Treated with RC220 Progress Report
- 2026-07-28 June 2026 Quarterly Activities Report and Appendix 4C Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
- 2026-07-03 Bellberry Ethics Approval Activates New HARNESS Trial Sites
- 2026-06-25 Racura Treats First Patient in HARNESS-1 Lung Cancer Trial
- 2026-06-16 Racura raised $34.3m to Advance Three Oncology Trials
More Health Care stocks
Most traded in the same sector.